Focus:
Deal News
-
19 September 2019
AstraZeneca revises Linzess deal with Ironwood Pharmaceuticals
AstraZeneca has revised its agreement with Ironwood Pharmaceuticals for irritable bowel syndrome with constipation (IBS-C) drug Linzess (linaclotide).
-
18 September 2019
Oncoheroes signs cancer asset licensing deal with Boehringer
US-based biotech company Oncoheroes Biosciences has entered into a licensing agreement with Boehringer Ingelheim for the intellectual property of an investigational cancer drug, volasertib.
-
17 September 2019
Lundbeck signs $1.95bn deal to buy Alder BioPharmaceuticals
Danish pharmaceutical company Lundbeck has signed a definitive agreement to acquire all outstanding shares of US-based Alder BioPharmaceuticals for a maximum consideration of $1.95bn.
-
17 September 2019
Amplyx licences Phase II anti-viral candidate from Novartis
US-based Amplyx Pharmaceuticals has obtained exclusive global rights from Novartis to a monoclonal antibody, MAU868, to prevent and treat BK viral disease.
-
16 September 2019
Aytu BioScience to buy Innovus Pharmaceuticals
Speciality pharmaceutical company Aytu BioScience has entered a definitive merger agreement to acquire consumer healthcare firm Innovus Pharmaceuticals.
-
13 September 2019
Inotrem secures funds to develop septic shock treatment
Biotechnology company Inotrem has secured series B funding to develop immunotherapy candidates targeting septic shock and chronic inflammatory conditions.
-
12 September 2019
Atomwise inks four new deals for AI-based drug discovery
US-based Atomwise has formed four new alliances to leverage its artificial intelligence (AI) technology for the discovery of new drugs across various therapeutic areas.
-
11 September 2019
Mallinckrodt to divest Canadian drug manufacturing unit for $250m
Biopharmaceutical firm Mallinckrodt has agreed to sell its contract development and manufacturing subsidiary BioVectra to an affiliate of private equity company H.I.G. Capital for approximately $250m.
-
11 September 2019
GSK to buy Sitari Pharmaceuticals from Avalon Ventures
UK-based pharmaceutical company GlaxoSmithKline (GSK) has signed a definitive agreement with Avalon Ventures to acquire Sitari Pharmaceuticals for an undisclosed amount.
-
11 September 2019
Sanofi to pay Lexicon $260m over terminated Zynquista alliance
Lexicon Pharmaceuticals has announced a $260m settlement with Sanofi over the termination of their alliance, which focused on the development and commercialisation of diabetes drug Zynquista (sotagliflozin).
Close
Close
Close
Go Top
